Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3102 ARTÍCULOS , VIENDO DEL 1231 AL 1245

Alpha-synuclein, lipids and Parkinson's disease

Ruipérez V, Darios F, Davletov B.

Prog Lipid Res. 2010 Oct;49(4):420-8. doi: 10.1016/j.plipres.2010.05.004. Epub 2010 May 23.

Downhill walking training in individuals with Parkinson's disease: a randomized controlled trial

Yang YR, Lee YY, Cheng SJ, Wang RY.

Am J Phys Med Rehabil. 2010 Sep;89(9):706-14. doi: 10.1097/PHM.0b013e3181e721c5.

Subthalamic nucleus deep brain stimulation changes speech respiratory and laryngeal control in Parkinson's disease

Hammer MJ, Barlow SM, Lyons KE, Pahwa R.

J Neurol. 2010 Oct;257(10):1692-702. doi: 10.1007/s00415-010-5605-5. Epub 2010 Jun 26.

Intranigral LPS administration produces dopamine, glutathione but not behavioral impairment in comparison to MPTP and 6-OHDA neurotoxin models of Parkinson's disease

Ariza D, Lima MM, Moreira CG, Dombrowski PA, Avila TV, Allemand A, Mendes DA, Da Cunha C, Vital MA.

Neurochem Res. 2010 Oct;35(10):1620-7. doi: 10.1007/s11064-010-0222-3. Epub 2010 Jun 26.

Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study

Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, Barone P, Lang AE, Olanow CW.

Ann Neurol. 2010 Jul;68(1):18-27. doi: 10.1002/ana.22060.

Continuous dopaminergic therapy in Parkinson disease: time to stride back?

Stoessl AJ.

Ann Neurol. 2010 Jul;68(1):3-5. doi: 10.1002/ana.22079.

Radioligands for the PET imaging of metabotropic glutamate receptor subtype 5 (mGluR5)

Mu L, Schubiger PA, Ametamey SM.

Curr Top Med Chem. 2010;10(15):1558-68. doi: 10.2174/156802610793176783.

Risk factors for falls in community-dwelling older people: a systematic review and meta-analysis

Deandrea S, Lucenteforte E, Bravi F, Foschi R, La Vecchia C, Negri E.

Epidemiology. 2010 Sep;21(5):658-68. doi: 10.1097/EDE.0b013e3181e89905.

Speech motor program maintenance, but not switching, is enhanced by left-hemispheric deep brain stimulation in Parkinson's disease

Jones HN, Kendall DL, Okun MS, Wu SS, Velozo C, Fernandez HH, Spencer KA, Rosenbek JC.

Int J Speech Lang Pathol. 2010 Oct;12(5):385-98. doi: 10.3109/17549507.2010.491870.

New therapeutic strategy for Parkinson's and Alzheimer's disease

Esposito E, Cuzzocrea S.

Curr Med Chem. 2010;17(25):2764-74. doi: 10.2174/092986710791859324.

Are dysautonomic and sensory symptoms present in early Parkinson's disease?

Tysnes OB, Müller B, Larsen JP.

Acta Neurol Scand Suppl. 2010;(190):72-7. doi: 10.1111/j.1600-0404.2010.01380.x.

Fatigue in Parkinson's disease: a short update

Beiske AG, Svensson E.

Acta Neurol Scand Suppl. 2010;(190):78-81. doi: 10.1111/j.1600-0404.2010.01381.x.

Protein aggregation in Parkinson's disease

Gundersen V.

Acta Neurol Scand Suppl. 2010;(190):82-7. doi: 10.1111/j.1600-0404.2010.01382.x.

Assessing vitamin D in the central nervous system

Holmøy T, Moen SM.

Acta Neurol Scand Suppl. 2010;(190):88-92. doi: 10.1111/j.1600-0404.2010.01383.x.

Current management of Parkinson's disease

Salawu F, Olokoba A, Danburam A.

Ann Afr Med. 2010 Apr-Jun;9(2):55-61. doi: 10.4103/1596-3519.64743.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias